{"filings":[{"id":91749,"accession_number":"0000012208-26-000034","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Bio-Rad Q1 GAAP net loss $527M ($19.55/share); net sales +1.1% to $592.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $592.1M, up 1.1% YoY; GAAP gross margin 52.3% (flat YoY), non-GAAP gross margin 53.1%.","GAAP net loss $527.1M (diluted EPS -$19.55) vs prior-year net income $64.0M ($2.29).","Non-GAAP net income $50.9M ($1.89 diluted EPS); non-GAAP operating income $39.3M, down from $63.0M.","Operating cash flow $108.1M; free cash flow $78.1M; repurchased ~176k shares during Q1.","Management cited challenging academic markets and Middle East conflict as headwinds."],"consensus_eps_estimate":null,"consensus_eps_actual":-19.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":592100000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91748,"accession_number":"0000012208-26-000024","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2026-04-24T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Stockholders approve Amended 2017 Incentive Award Plan, adding 335,000 shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plan approved with 6.85M for, 105k against; extends expiration to March 18, 2036.","Increases share reserve by 335,000 shares for future equity grants.","Stockholder proposal on dual-class capital structure defeated (1.47M for, 5.46M against).","All six director nominees elected; KPMG ratified as auditors for FY 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102039,"accession_number":"0000012208-26-000012","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Bio-Rad updates Sartorius AG 2025 financials: sales €3.54B, net profit €230M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sartorius AG 2025: sales €3,538.1M, gross profit €1,636.7M, EBIT €542.6M, net profit €230.4M.","Balance sheet: current assets €1,766.2M, non-current €7,951.1M, total equity €3,867.2M.","Operating cash flow €837.0M; investing outflow €513.7M; financing outflow €591.4M.","Update follows Sartorius’ Feb 16, 2026 release; Bio-Rad’s 10-K investment disclosure updated accordingly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102038,"accession_number":"0000012208-26-000007","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Bio-Rad Q4 GAAP operating loss $118.9M; non-GAAP EPS down to $2.51 from $2.90","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP operating loss $118.9M vs income $58.4M YoY; gross margin down 140bps to 49.8%.","Q4 non-GAAP operating income $83.0M (down 10% YoY); non-GAAP EPS $2.51 vs $2.90.","Full-year non-GAAP operating income $311.6M vs $331.3M; EPS $9.92 vs $10.31.","Q4 GAAP net income $720.0M vs $715.8M loss YoY driven by equity investment fair value changes.","CEO cites geopolitical uncertainty and academic funding pressure; Stilla acquisition integrated."],"consensus_eps_estimate":null,"consensus_eps_actual":27.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":2583200000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118395,"accession_number":"0000012208-25-000076","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Bio-Rad posts GAAP net loss of $342M in Q3 2025; non-GAAP EPS rises to $2.26","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $653.0M, up slightly from $649.7M year-over-year.","GAAP net loss $341.9M ($12.70 loss per diluted share) vs net income $653.2M in Q3 2024.","Non-GAAP net income $60.8M ($2.26 per share) vs $56.3M ($2.02) in prior year.","GAAP gross margin declined to 52.6% from 54.8%; non-GAAP gross margin declined to 53.5% from 55.6%.","CEO cited disciplined cost management for better-than-expected operating margin despite funding headwinds."],"consensus_eps_estimate":null,"consensus_eps_actual":1.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":1890000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134822,"accession_number":"0000012208-25-000057","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2025-09-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bio-Rad co-founder and Director Emeritus Alice Schwartz dies at 99","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alice N. Schwartz, co-founder of Bio-Rad, passed away on September 25, 2025, at age 99.","She co-founded Bio-Rad in 1952 with her husband David and developed the company's first thyroid test kit in the 1960s.","Schwartz served as an active Board member until 2022 and was named Director Emeritus.","Her contributions included the innovation that marked Bio-Rad's entry into clinical diagnostics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134821,"accession_number":"0000012208-25-000054","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2025-08-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bio-Rad holds ddPCR webinar; no new financial or product details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Informational webinar on Droplet Digital PCR portfolio held August 26, 2025.","President/COO Jon DiVincenzo and CFO Roop Lakkaraju hosted the event.","Slide presentation and replay posted on investor relations page for one year.","No specific product performance, revenue, or guidance figures provided in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134820,"accession_number":"0000012208-25-000051","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Bio-Rad Q2 revenue up 2% to $652M; completes Stilla acquisition","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 revenue $651.6M (+2.1% YoY); GAAP net income $317.8M vs loss $2,165.5M (prior year included Sartorius losses).","Non-GAAP EPS $2.61 vs $3.11; non-GAAP operating income $88.6M vs $106.9M, reflecting margin compression.","GAAP gross margin 53.0% vs 55.6%; non-GAAP gross margin 53.7% vs 56.4%, down on product mix and costs.","Completed acquisition of Stilla Technologies, expanding digital PCR portfolio with QX Continuum and QX700 systems."],"consensus_eps_estimate":null,"consensus_eps_actual":13.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":1237000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134819,"accession_number":"0000012208-25-000047","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Bio-Rad appoints Rajat Mehta as EVP Global Commercial Operations; Crowley retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rajat Mehta appointed EVP, Global Commercial Operations, effective August 4, 2025.","Mehta joins from Labcorp (SVP) and Thermo Fisher Scientific; holds Wharton MBA.","Mike Crowley retiring after 26 years; will stay as employee through September 2025 for transition.","Board approved change on July 23, 2025; Crowley ceases as executive officer on August 4."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151746,"accession_number":"0000012208-25-000032","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Bio-Rad completes acquisition of Stilla Technologies on June 30, 2025","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Affiliate of Bio-Rad completed purchase of all equity interests of Stilla Technologies, a French corporation.","Transaction was previously announced on February 13, 2025.","No financial terms of the acquisition were disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151745,"accession_number":"0000012208-25-000025","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bio-Rad Q1 revenue falls 4% to $585M; full-year 2025 outlook moderated on uncertainty","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $585.4M, down from $610.8M YoY; GAAP gross margin 52.3% vs 53.4%.","GAAP net income $64.0M ($2.29 EPS) vs $383.9M ($13.45 EPS) in Q1 2024.","Non-GAAP net income $71.0M ($2.54 EPS) vs $65.3M ($2.30 EPS) YoY.","CEO cites market uncertainty; moderating full-year 2025 outlook.","Non-GAAP gross margin 53.8%, slightly down from 54.2% a year ago."],"consensus_eps_estimate":null,"consensus_eps_actual":2.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":585400000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151744,"accession_number":"0000012208-25-000022","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bio-Rad shareholders elect directors, ratify KPMG, reject severance proposal","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All six director nominees elected: Litherland, Pinkston (Class A); Edwards, Hinckley, A. Schwartz, N. Schwartz (Class B).","Ratification of KPMG as independent auditor for FY2025 approved: 7,151,391 for, 51,910 against, 2,176 abstain.","Stockholder proposal on executive severance approval failed: 923,215 for, 6,125,784 against, 3,277 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170604,"accession_number":"0000012208-25-000009","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Bio-Rad discloses Sartorius AG FY2024 results: revenue €3.38B, net profit €137.4M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sartorius AG reported FY2024 sales revenue of €3,380.7M, gross profit €1,524.4M, EBIT €392.6M.","Net profit for FY2024 was €137.4M; operating cash flow €976.2M, investing cash flow -€425.8M.","As of Dec 31, 2024, Sartorius had total assets €10,103.0M, total liabilities €6,205.2M, equity €3,897.8M.","Bio-Rad does not assume responsibility for Sartorius's publicly disclosed figures; refers to Sartorius's annual report.","Update relates to Bio-Rad's Investment in Sartorius AG section of its 2024 10-K filed Feb 14, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170603,"accession_number":"0000012208-25-000004","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["2.02","2.05","8.01","9.01"],"status":"ready","headline":"Bio-Rad Q4 revenue down 2%; launches restructuring (5% workforce cut) and offers to acquire Stilla","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q4 2024 revenue $667.5M vs $681.2M YoY; GAAP operating income $58.4M vs $95.3M.","Full-year 2024 revenue $2,566.5M vs $2,671.2M; non-GAAP op margin 12.9% vs 14.2%.","Restructuring plan eliminates ~5% of workforce; expected cost $45-50M, $30-35M charge in Q1 2025.","Binding offer to acquire all equity of Stilla Technologies (digital PCR); close expected by Q3 2025.","No deal value disclosed; acquisition subject to regulatory approvals and employee consultation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187587,"accession_number":"0000012208-24-000062","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bio-Rad Q3 revenue up 2.8% to $649.7M; net income $653.2M on Sartorius gain","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $649.7M, +2.8% YoY; currency-neutral +3.4%; Clinical Diagnostics grew 5.6% to $388.8M.","Life Science segment sales $260.9M, -1.0% YoY, citing ongoing biotech/biopharma weakness.","Income from operations fell to $64.5M from $90.9M; net income surged to $653.2M ($23.34 EPS) on Sartorius fair value change.","Gross margin improved to 54.8% from 53.1% YoY; effective tax rate 24.2%.","Appointed Jon DiVincenzo as President and COO; CEO cites gradual biopharma recovery and new leadership."],"consensus_eps_estimate":null,"consensus_eps_actual":-39.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":1899025000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204077,"accession_number":"0000012208-24-000056","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Bio-Rad amends bylaws to update stockholder meeting procedures and proxy rules","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board amended Bylaws effective Sept 6, 2024, adding electronic stockholder meeting participation and universal proxy rule compliance.","Eliminated requirement to make stockholder list available at meetings.","Clarified CEO role as separate from President; required proxy solicitors to use non-white proxy card color.","Updated procedures for director nominations and other business proposals, including Rule 14a-19 universal proxy rules.","Made other administrative, clarifying, and conforming changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204076,"accession_number":"0000012208-24-000054","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2024-08-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Bio-Rad appoints Jon DiVincenzo as President and COO, replacing retiring Andy Last","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["DiVincenzo joins from Labcorp, where he was EVP and President, Central Laboratories & International.","Start date September 9, 2024; Last retires September 5, 2024.","Compensation includes $665k base salary, $2.5M RSU grant, $1.3M sign-on bonus, and relocation support.","Norman Schwartz remains CEO and Chairman, no longer President.","DiVincenzo brings 30+ years of life science and diagnostics experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204075,"accession_number":"0000012208-24-000050","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Bio-Rad Q2 net sales down 6.3% YoY; Life Science weak, Diagnostics up 2.1%; board adds $500M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net sales $638.5M, -6.3% YoY; Life Science $250.5M (-16.5%), Diagnostics $387.9M (+2.1%).","Gross margin improved to 55.6% from 53.2%; operating income $101.5M vs $89.6M YoY.","Net loss $2,165.5M ($76.26 diluted EPS) mainly due to non-cash fair value adjustment of Sartorius investment.","CEO expects more modest pace of market recovery than originally anticipated.","Board authorized additional $500M share repurchase; total available ~$578M as of July 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-62.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":1249296000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220778,"accession_number":"0000012208-24-000036","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bio-Rad Q1 net sales down 9.8% to $610.8M; Life Science segment falls 25.3% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $610.8M, down 9.8% YoY (currency-neutral -9.6%); operating income $44.7M vs $61.9M.","Life Science segment $241.7M (-25.3% YoY) due to biotech/biopharma weakness; Clinical Diagnostics $368.6M (+4.7%) grew.","Net income $383.9M ($13.45 diluted) vs $69.0M ($2.32), largely from fair value changes of Sartorius AG equity holdings.","CEO Norman Schwartz: Q1 in line with expectations; cautiously optimistic for gradual biopharma recovery in H2 2024.","Effective tax rate 21.8% vs 18.7% a year ago, affected by equity securities treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":13.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":610820000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220777,"accession_number":"0000012208-24-000031","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2024-04-26T23:59:59+00:00","items":["5.02","5.07","7.01","9.01"],"status":"ready","headline":"Bio-Rad Life Science Group President Simon May resigns; James Barry appointed as successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Simon May resigns as EVP & President, Life Science Group, effective May 1, 2024, to pursue another opportunity.","James J. Barry promoted from SVP of Global Manufacturing to succeed May as EVP & President, Life Science Group, effective May 1, 2024.","Stockholders approved amendment to 2017 Incentive Award Plan, extending expiration to 2034 and allowing non-employee director participation.","Principal accounting officer role transferred to CFO Roop K. Lakkaraju, replacing interim Tania DeVilliers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}